JPMorgan analyst Anupam Rama lowered the firm’s price target on Solid Biosciences (SLDB) to $12 from $15 and keeps an Overweight rating on the shares. The firm updated models in the Smid-cap biotechnology space.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.